Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,202 total articles
Novo Nordisk (NVO) has been hit hard after weaker 2026 guidance and a U.S. pricing deal, but its GLP-1 demand and new oral pill adoption give a clear rebound scenario. This trade idea lays out a mid-term swing entry, explicit stop and target levels, catalysts to watch, and the risks that could invalidate the trade.
Patterson-UTI (PTEN) trades like a capital-return vehicle more than a growth story. With $289M in free cash flow, an EV/EBITDA of 4.6, a dividend yield near 3.7% and a large remaining repurchase authorization, the company can choose to buy back stock or sustain the dividend instead of chasing higher-risk diversification. The trade: go long for a mi…
Shares of LKQ Corporation have pulled back into the low $30s after a rough 2025 and index reweighting. The combination of solid free cash flow ($722M), a 3.5% yield, delevered balance sheet (debt/equity 0.63), and an active sale process for the Specialty segment creates a near-term catalyst-rich setup. I propose a mid-term swing trade to capture a …
The Walt Disney Company is cheaper than it has been in years on a variety of metrics, just turned streaming profitable, and is deploying a $7 billion buyback while leaning into high-margin parks and experiences. With a market cap near $190B, a forward P/E around 16 and free cash flow north of $7B, DIS presents an asymmetric risk/reward. I rate it S…
SoFi reported accelerated revenue growth and profitability in Q4 2025 and has optionality across lending, payments and banking. At roughly $26.9B market cap and a current price near $21.38, the stock looks mispriced relative to a plausible re-rate as revenue and EPS expand. This trade idea outlines a mid-term long with a defined entry, stop and tar…
PayPal (PYPL) has been punished hard after weak Q4 results, a profit warning and a CEO transition. The stock trades near its 52-week low, with a P/FCF around 6.7, free cash flow of $5.56B and an enterprise value under $40B. Technicals are brutally oversold and short interest is moderate - a setup for a value-driven bounce. This trade idea lays out …
Mitsubishi Heavy Industries (MHVYF) shows clear technical strength, elevated short interest and recent buy-side narrative that together support a bullish position. Enter around $32.00 with a $29.00 stop and a $38.00 target for a position intended to run through potential full-year upside over the next 3-6 months.
KSA (iShares MSCI Saudi Arabia ETF) looks positioned for a long-term trade: attractive yield (3.41%), reasonable valuation (P/E ~16.7), and technical momentum near the 20/50-day EMAs. We recommend a long trade with clear entry, stop and a target near the 52-week high, balanced by geopolitics and commodity-risk considerations.
Nordic American Tankers (NAT) trades near $4.25 with a market cap under $900M, an 8.45% dividend yield and recent fleet additions that should support cash flow. Technicals show the stock near a 52-week high while volume and insider buying add conviction. This trade idea lays out an actionable long entry with a clear stop and target and a rationale …
Amazon's share price has pulled back on heavy 2026 AI infrastructure spending headlines, but the selloff creates a targeted long-term opportunity. AWS's $142B revenue run rate and 24% growth plus immediate monetization of new capacity argue for patience. Trade plan: enter at $205.00, stop $190.00, target $260.00 over a 180-trading-day horizon.
CrowdStrike (CRWD) has retraced roughly 30% from its 52-week high while retaining strong growth, solid free cash flow, and a conservative balance sheet. Technicals show oversold conditions and short interest that can fuel a squeeze. I’m upgrading to Buy with a clear entry, stop and target for a mid-term swing trade.
PayPal plunged after a weak quarter and lowered guidance, but the sell-off appears overextended. Balance-sheet strength, meaningful free cash flow and single-digit valuation create an asymmetric risk/reward for a mid-term (45 trading days) long trade. This is a tactical trade, not a statement that all operational issues are solved.
Crown Holdings' sizable free cash flow and solid return on equity support a buy-rated trade. Valuation metrics - P/E ~13.5, EV/EBITDA ~11.7 and price/free cash flow ~12.7 - leave room for a re-rating if commodity costs stabilize and beverage demand holds. Technicals and dividend support create a favorable entry around $110 with a clear stop under n…
W&T Offshore (WTI) is a small-cap Gulf of Mexico producer with a levered balance sheet and a cheap trading multiple. If oil prices regain momentum, WTI stands to re-rate quickly — but the trade carries execution and credit risk. This plan lays out a mid-term swing trade (45 trading days) that targets a run past last year’s highs while capping downs…
Amazon fell into a broad AI-capex panic despite AWS showing healthy monetization and high margins. The stock is oversold (RSI ~27), trading well below its moving averages, and the pullback offers a controlled, asymmetric trade with a mid-term horizon. Entry at $205.65, stop at $195.00, target $255.00.
Merck (MRK) is a pragmatic buy into 2026. The stock trades at roughly a mid-teens P/E, produces strong free cash flow ($13.05B), and still benefits from Keytruda momentum and an expanding animal health business. Near-term guidance that missed Street estimates and binary clinical readouts create a time-sensitive window—the fundamentals argue for acc…
Veeva Systems is deep in oversold territory after a sharp pullback. Strong free cash flow, a fresh $2 billion buyback, and an expanding addressable market for regulated cloud workflows argue for a mean-reversion trade. This idea lays out a precise entry, stop and target with rationale and risks.
Workday (WDAY) has been punished by a negative narrative around workforce moves and activist exits, but the business still generates meaningful free cash flow, has a healthy balance sheet, and sits at technically oversold levels. This trade idea lays out five reasons to buy, a concrete entry/stop/target plan for a mid-term (45 trading days) swing, …
Kroger (KR) looks attractive as a long trade for risk-conscious investors. The business generates meaningful free cash flow ($2.27B) and returns capital through dividends (next payable 03/01/2026). Recent operational catalysts - from automation in cold-chain warehouses to expanded AI personalization - should lift margins and customer retention over…
Arm's licensing model sits at the orchestration layer of an AI stack pivot toward distributed, power-efficient compute. With data-center royalties more than doubling YoY and hyperscaler capex commitments, Arm can convert model scale into recurring, high-margin revenue. Valuation is rich today, so the trade uses a disciplined entry and stop to captu…
Rubrik (RBRK) is an industry fixture in cloud data management and cyber recovery. Shares have retraced from last summer’s highs and are trading near technical oversold levels while the company shows improving subscription momentum and positive free cash flow. This is a disciplined, catalyst-driven buy: enter at $50.00, stop at $44.00, primary targe…
NetScout's mix of strong free cash flow, negligible debt, and incremental AI/ML enhancements to its nGeniusONE platform support a tactical long. Valuation looks reasonable (P/E ~20.8, EV/EBITDA ~8.6) and the balance sheet is clean; if management converts recent operational work into margin expansion, shares can re-rate toward consensus analyst upsi…
We upgrade Bar Harbor Bankshares (BHB) to Buy. The story here is modest: a reasonably valued regional bank (market cap ~$595M) trading slightly above its longer-term moving averages, an attractive dividend yield (~3.5%), and consecutive quarter earnings beats that point to operating stability. Our trade is a mid-term swing targeting renewed P/E exp…
Rubrik plunged with the broader software selloff but still shows double-digit ARR growth, positive free cash flow and an attractive risk/reward. I recommend buying RBRK with a tight stop and a clear target as sector sentiment normalizes and Zero Trust spending accelerates.
Biogen reported stable FY25 earnings and a Q4 beat, with Alzheimer's therapy Leqembi driving growth while legacy multiple sclerosis drugs decline. Valuation looks reasonable (market cap ~$29.5B, P/E ~22.8) and free cash flow is healthy, but MS franchise pressure and execution risk argue for a controlled, horizon-based trade rather than an aggressiv…
